A recent randomized phase 2 study of sunitinib or cediranib in alveolar soft part sarcoma established benchmark activity for commonly used tyrosine kinase inhibitors. The impact of TKIs, as well as immunotherapy, has redefined treatment paradigms and greatly improved outcomes for this historically dismal sarcoma.

This content is only available via PDF.

Article PDF first page preview

Article PDF first page preview
You do not currently have access to this content.